August 25, 2025
4 min watch
Key takeaways:
- mPATH Health has modules for identifying patients in need of colorectal, breast and lung cancer screening.
- mPATH Health reaches out to patients directly to inform and educate them.
A cloud-based platform helps health care centers identify patients who are overdue for routine cancer screening and aids with uptake through direct outreach, as well as education.
mPATH Health is currently in use at five health care sites with modules for colorectal, lung and breast cancer screening. It uses automated text messages and patient portals to connect with patients about tests they may need to get them started on their journey.
“mPATH Health empowers people to live their fullest lives with personalized health information,” David P. Miller Jr., MD, MS, FACP, the company’s founder and CEO, said. “Our main focus is on cancer screening because we know that by helping people get screened for cancer, we can find it early when it’s easiest to treat, saving lives and letting them be around years later for what matters most to them.”
Miller anticipates future modules for HIV prevention as well as fertility preservation for adolescents and young adults diagnosed with cancer.
mPATH Health is one of just 14 startups selected for the 2025 CancerX Accelerator cohort, a group of innovative digital health and AI startups focused on addressing critical challenges in oncology. The program is hosted by Moffitt Cancer Center and launched in collaboration with the Office of the National Coordinator for Health Information Technology and the Office of the Assistant Secretary for Health.
The CancerX Accelerator program provides participating startups with access to industry champions, experienced mentors and a wide range of support, from product feedback and pilot opportunities to potential commercial agreements.
“One of the most valuable aspects for us coming out of CancerX was the ability to receive mentorship from leaders within the health care space,” Miller said. “This really helped us understand what’s important to health systems, what’s important to payers and how can we jointly work together to accomplish our goals of improving cancer care.
“Everybody knows that screening for cancer is important, but what CancerX let us do is talk with leaders who could pull back the curtain so we could understand the internal processes that any solution has to go through before it will be adopted,” he added.
In this video, Miller details key reasons for participating in the CancerX Accelerator, collaborations it has already provided the company and advice for the 2026 CancerX Accelerator cohort.
As the official media partner of the CancerX 2025 Accelerator cohort, Healio will showcase key breakthroughs and achievements through exclusive interviews with this year’s startups as well as alumni groups from the 2024 program.
Applications for the 2026 CancerX Accelerator cohort will open Sept. 2, 2025, exclusively for CancerX members, with public applications opening Sept. 9, 2025. Join the CancerX community here.
References:
For more information:
David P. Miller Jr., MD, MS, FACP, can be reached at dave@mpathhealth.com.
